The increased CAF-transforming ability of these clinical osimertinib NSCLC cells was associated with increased signaling in MET, Akt, EGFR, and vimentin, all of which contributed towards ceullar survival, proliferation and EMT [24, 25]. The gene discussed is MET; the disease is non-small cell lung carcinoma.